Project Grant R03CA292985
Award Date
7/12/24
Completion Date
6/30/26
Dollars Obligated
$156K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Emory University provides $659,498 in funding to investigate racial disparities in the mechanisms of prostate cancer metastasis. The research aims to analyze differential pathway activity, particularly related to the FGFR3 signaling and oxidative phosphorylation (OXPHOS) pathways, and their impact on metastasis in African American men. The project will leverage in vitro and in vivo models, as...
This Project Grant award of $704,882, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the genetic basis of prostate cancer risk in African American families. The key objectives are to: Enroll additional eligible first- and second-degree affected and unaffected family members from the existing RESPOND cohort to study genetic factors contributing to familial prostate cancer risk in African American...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco to investigate the biological mechanisms contributing to racial disparities in outcomes for head and neck cancer, particularly oral squamous cell carcinoma, in Black patient populations. The research aims to: 1) Develop a prognostic model using gene expression signatures to predict disease progression risk in...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
The National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), awarded a $613,220 project grant to the University of Southern California (USC) to investigate the contribution of germline copy number variations (CNVs) to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The 5-year project, starting February 1, 2025, will combine imputation and sequencing-based approaches to comprehensively assess CNVs...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $577,529 to Health Research, Inc. to investigate the relationship between accelerated ribosomal DNA (rDNA) methylation age and early-onset prostate cancer in African American patients. The main objectives are to: 1) determine if African American prostate cancer patients exhibit higher rDNA methylation age at diagnosis compared to age-matched...
The National Cancer Institute (NCI) awarded a 5-year, $162,160 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Ohio State University to improve the assessment of patient-reported outcomes (PROs) among Black/African-American cancer patients. The research will involve qualitative interviews with Black cancer patients and their providers to understand barriers and facilitators to completing PROs and social determinants of health (SDH) measures. This knowledge will inform the...
This Project Grant award of $717,667, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports the development of an Artificial Intelligence-enabled Stroma-Weighted Automated Grading (SWAG) system to improve risk stratification and early detection of lethal prostate cancer phenotypes in Black men. The key products and services to be delivered under this award include: Annotating H&E and multiphoton microscopy/second harmonic generation...
This Project Grant award, totaling $589,591, was provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353). The objective of this 5-year study is to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma. The key products and services to be delivered under this award include: Examining differences in the receipt and quality of Hodgkin lymphoma...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will fund research to develop a minimally invasive, plasma-based diagnostic method for early detection of prostate cancer in African American men. The $475,759 award to The Children's Hospital Corporation (Boston Children's Hospital) will support the investigation of two next-generation sequencing-based methods - cell-free DNA fragmentation profiling and...